Trump weighs Sharpless for FDA chief, signaling shift away from Kennedy vaccine agenda
TL;DR
The Trump administration is vetting Norman Sharpless, a former director of the National Cancer Institute and former acting FDA chief, to lead the FDA, signaling a move away from Robert F. Kennedy Jr.’s vaccine-policy agenda toward more conventional leadership ahead of the midterms. Sharpless has criticized certain FDA vaccine-policy changes, and other candidates include Alkermes CEO Richard Pops and acting commissioner Kyle Diamantas as officials seek stability at the agency amid turnover and policy fights, including debates over abortion-pill access.
- Trump admin vetting critic of RFK vaccine policies for FDA chief, sources say CNN
- Acting FDA commissioner pledges to prevent political interference in rare disease meeting Endpoints News
- Acting US FDA chief meets with rare disease groups to mend fences Reuters
- This Week at FDA: WH reviewing candidates for FDA commissioner, Diamantas’ rare disease outreach, and more RAPS.org
- FDA Faces Pressure to Standardize Regulatory Frameworks for Gene Therapy Development geneonline.com
Want the full story? Read the original reporting
Read on CNN